{
    "nctId": "NCT00217399",
    "briefTitle": "Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer",
    "officialTitle": "A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Complete Response + Partial Response + Stable Disease > 24 Weeks",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer\n* Metastatic disease\n* Measurable disease, defined as \\>=1 unidimensionally measurable lesion, including \\>= 1 of the following:\n\n  * Lesion \\>= 10 mm on CT scan (5 mm sections)\n  * Lesion \\>= 20 mm on CT scan or MRI (10 mm sections)\n  * Bone disease that is \\>= 10 mm on MRI\n  * Lytic bone lesions that are \\>= 10 mm on CT scan (with 5 mm sections) OR \\>= 20 mm on plain film or CT scan (with 10 mm sections)\n  * Lesion \\>= 10 mm on physical exam\n* Patients must have received \\>= 1 prior aromatase inhibitor in either the adjuvant or metastatic setting and must have had either disease recurrence or disease progression on a prior aromatase inhibitor therapy\n* No brain metastases diagnosed within the past 6 months OR previously untreated brain metastases\n* Estrogen receptor-positive and/or progesterone receptor-positive, defined as \\> 1% staining by immunohistochemistry or \\> 10 fmol/mg of protein by radio-ligand dextran-coated steroid binding assay\n* Postmenopausal, as defined by 1 of the following:\n\n  * Prior bilateral oophorectomy\n  * No menses for \\>= 12 months in patients with an intact uterus\n  * Follicle-stimulating hormone (FSH) in postmenopausal range in patients \\< 60 years of age who have had a prior hysterectomy or have been amenorrheic for \\>= 3 months\n  * Age \\>= 60 years\n  * Pre- or perimenopausal patients receiving monthly injections of goserelin at a dose of 3.6 mg are eligible\n* ECOG 0-2\n* More than 3 months\n* Absolute neutrophil count \\>= 1,500/mm3 Platelet count \\>= 100,000/mm3 No bleeding diathesis\n* Bilirubin =\\< 1.5 times upper limit of normal (ULN AST and ALT =\\< 2.5 times ULN\n* Systolic blood pressure (BP) \\< 150 mm Hg and diastolic BP \\< 100 mm Hg on at least one reading prior to study entry No uncontrolled hypertension\n* None of the following within the past 6 months:\n\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Myocardial infarction\n  * Cardiac arrhythmia with hemodynamic compromise\n* Not pregnant or nursing\n* Able to swallow oral medication\n* No known HIV positivity\n* No ongoing or active infection\n* No psychiatric illness or social situation that would preclude study compliance\n* No other active invasive malignancy within the past 5 years except nonmelanoma skin cancer or treated carcinoma in situ of the cervix\n* No other uncontrolled illness\n* More than 4 weeks since prior chemotherapy\n* No more than 2 prior chemotherapy regimens for metastatic disease\n* At least 8 weeks since prior anastrozole therapy\n* Concurrent steroids allowed if dose is stable\n* More than 4 weeks since prior radiotherapy\n* More than 4 weeks since prior major surgery\n* Recovered from prior therapy\n* No prior sorafenib\n* No concurrent therapeutic anticoagulation\n* Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided PT and PTT are =\\< 1.5 times ULN\n* No concurrent agents that may interact with sorafenib, including any of the following:\n\n  * Hypericum perforatum (St. John's wort)\n  * Rifampin\n  * P450 CYP3A4 enzyme-inducing anticonvulsants (e.g., phenytoin, carbamazepine, or phenobarbital)\n* No other concurrent investigational agents\n\nExclusion Criteria:\n\n* estrogen receptor status unknown\n* history of myocardial infarction within 6 months\n* performance status 3\n* performance status 4\n* premenopausal\n* progesterone receptor status unknown\n* HIV positive",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}